Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Circulating Tumor Cells Predict NSCLC Survival

Key clinical point: Circulating tumor cell count is an independent prognostic indicator of both progression-free and overall survival in patients with advanced non–small cell lung cancer.

Major finding: CTC counts of at least 5 cells per 7.5 mL were associated with reduced overall survival (hazard ratio, 2.75; P less than .001).

Study details: A retrospective analysis involving 550 patients with NSCLC from nine centers.

Disclosures: The investigators disclosed financial relationships with AstraZeneca, Novartis, Pfizer, and others.

Citation:

Lindsay et al. ELCC 2019, Abstract 21O.